GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (STU:6HN) » Definitions » Institutional Ownership

Everest Medicines (STU:6HN) Institutional Ownership : 5.78% (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Everest Medicines Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Everest Medicines's institutional ownership is 5.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Everest Medicines's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Everest Medicines's Float Percentage Of Total Shares Outstanding is 0.00%.


Everest Medicines Institutional Ownership Historical Data

The historical data trend for Everest Medicines's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Institutional Ownership Chart

Everest Medicines Historical Data

The historical data trend for Everest Medicines can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 7.03 6.99 6.89 6.73 6.66 6.65 5.70 5.68 5.81 5.78

Everest Medicines Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Everest Medicines Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Everest Medicines Headlines

No Headlines